Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255410 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01255410 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants.
The verdict
NCT01255410, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
People who are infected with human metapneumovirus (HMPV) may develop upper and lower respiratory illnesses. Children are particularly sensitive to HMPV infection. This study will evaluate the safety and immune response of an HMPV vaccine in healthy adults, HMPV-seropositive children, and HMPV-seronegative infants and children.
Interventions
- BIOLOGICAL Placebo Vaccine
- BIOLOGICAL 10^6 PFU rHMPV-Pa vaccine
- BIOLOGICAL 10^5 PFU rHMPV-Pa vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01255410
The ClinicalTrials.gov registry entry for NCT01255410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Vaccine is the first listed.
NCT01255410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01255410 about?
NCT01255410 is a clinical study titled "Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine". People who are infected with human metapneumovirus (HMPV) may develop upper and lower respiratory illnesses. Children are particularly sensitive to HMPV infection. This study will evaluate the safety and immune response of an HMPV vaccine in healthy adults, HMPV-seropositive children, and HMPV-seron...
What is the current status of trial NCT01255410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01255410?
The interventions under investigation include: Placebo Vaccine (BIOLOGICAL), 10^6 PFU rHMPV-Pa vaccine (BIOLOGICAL), 10^5 PFU rHMPV-Pa vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01255410?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.